Compare · AXSM vs TNYA
AXSM vs TNYA
Side-by-side comparison of Axsome Therapeutics Inc. (AXSM) and Tenaya Therapeutics Inc. (TNYA): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both companies sit in the Health Care sector. AXSM focuses on Biotechnology: Pharmaceutical Preparations, while TNYA focuses on Biotechnology: Biological Products (No Diagnostic Substances).
- AXSM is the larger of the two at $12.68B, about 83.7x TNYA ($151.5M).
- AXSM has been more active in the news (23 items in the past 4 weeks vs 14 for TNYA).
- AXSM has more recent analyst coverage (25 ratings vs 7 for TNYA).
- Company
- Axsome Therapeutics Inc.
- Tenaya Therapeutics Inc.
- Price
- -
- -
- Market cap
- $12.68B
- $151.5M
- 1M return
- -
- -
- 1Y return
- -
- -
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Biological Products (No Diagnostic Substances)
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2015
- 2021
- News (4w)
- 23
- 14
- Recent ratings
- 25
- 7
Axsome Therapeutics Inc.
Axsome Therapeutics, Inc., a biopharmaceutical company, engages in the development of novel therapies for central nervous system (CNS) disorders in the United States. Its product pipeline includes AXS-05 for the treatment major depressive disorder and resistant depression disorders; and that is in the Phase III clinical trial for the treatment of Alzheimer's disease agitation, as well as that has completed phase II clinical trial for the treatment of smoking cessation. The company is also developing AXS-07 for the treatment of migraine; AXS-12 for the treatment of narcolepsy; and AXS-14 for the treatment of fibromyalgia. Axsome Therapeutics, Inc. has a research collaboration agreement with Duke University for evaluating AXS-05 in smoking cessation. The company was incorporated in 2012 and is based in New York, New York.
Tenaya Therapeutics Inc.
Tenaya Therapeutics, Inc. develops therapeutics for heart failure. It offers cellular regeneration platform, that enables in vivo reprogramming of cardiac fibroblasts into cardio myocytes by delivering proprietary transcription factors; gene therapy platform, that enables the targeted delivery of a payload to cardiac fibroblasts; and precision medicine platform, which provides personalized medicine approach to treat heart disease. The company was incorporated in 2016 and is based in South San Francisco, California.
Latest AXSM
- Director Saad Mark E converted options into 1,429 shares, increasing direct ownership by 14% to 11,431 units (SEC Form 4)
- Director Jeffs Roger converted options into 1,429 shares, increasing direct ownership by 2% to 58,939 units (SEC Form 4)
- Director Mahony Susan converted options into 1,429 shares and sold $145,017 worth of shares (600 units at $241.69) as part of a pre-agreed trading plan (SEC Form 4)
- Director Coleman Mark converted options into 1,429 shares and sold $160,107 worth of shares (643 units at $249.00) as part of a pre-agreed trading plan, increasing direct ownership by 3% to 30,389 units (SEC Form 4)
- SEC Form 144 filed by Axsome Therapeutics Inc.
- SEC Form 144 filed by Axsome Therapeutics Inc.
- SEC Form 144 filed by Axsome Therapeutics Inc.
- Axsome Therapeutics Inc. filed SEC Form 8-K: Leadership Update, Financial Statements and Exhibits
- Axsome Therapeutics Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits
- SEC Form 4 filed by Director Coleman Mark
Latest TNYA
- Tenaya Therapeutics Announces Interim Data from MyPEAK™-1 Showing Treatment of MYBPC3-associated HCM with TN-201 Gene Therapy Resulted in Consistent Signs of Cardiac Remodeling and Reductions in Symptoms
- Tenaya Therapeutics to Announce New Interim Data from MyPEAK™-1 Phase 1b/2 Trial of TN-201 for Adults with MYBPC3-Associated HCM on Wednesday, June 3, 2026
- SEC Form 4 filed by Director Williams R Sanders
- SEC Form 4 filed by Director Walsh Jeffrey T.
- SEC Form 4 filed by Director Stehman-Breen Catherine
- SEC Form 4 filed by Director Srivastava Deepak
- SEC Form 4 filed by Director Parschauer Karah Herdman
- SEC Form 4 filed by Director Lee June
- SEC Form 4 filed by Director Burroughs Amy L.
- Tenaya Therapeutics Inc. filed SEC Form 8-K: Leadership Update, Submission of Matters to a Vote of Security Holders